Evidence map›Paper›PMID 37934252›Full record

ReviewCancer chemotherapy and pharmacology2024

Platinum-based chemotherapy in metastatic prostate cancer: what possibilities?

Martina Catalano, Andrea Lapucci, Stefania Nobili, Irene De Gennaro Aquino, Ismaela Anna Vascotto, Lorenzo Antonuzzo, Donata Villari, Gabriella Nesi, Enrico Mini, Giandomenico Roviello

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer chemotherapy and pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Targeting prostate adenocarcinoma tumor microenvironment via cancer nanotheranostics: a comprehensive update on improved roadmap for disease diagnosis, therapy and management.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Martina CatalanoDepartment of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, 50139, Florence, Italy. martina.catalano@unifi.it.ORCID 0000-0003-1856-2848
Andrea LapucciDepartment of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, 50139, Florence, Italy.
Stefania NobiliDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, 50139, Florence, Italy.
Irene De Gennaro AquinoSchool of Human Health Sciences, University of Florence, 50134, Florence, Italy.
Ismaela Anna VascottoSchool of Human Health Sciences, University of Florence, 50134, Florence, Italy.
Lorenzo AntonuzzoDepartment of Experimental and Clinical Medicine, University of Florence, 50134, Florence, Italy.
Donata VillariDepartment of Experimental and Clinical Medicine, University of Florence, 50134, Florence, Italy.
Gabriella NesiDepartment of Health Sciences, Section of Pathological Anatomy, University of Florence, 50139, Florence, Italy.
Enrico MiniDepartment of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, 50139, Florence, Italy.
Giandomenico RovielloDepartment of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, 50139, Florence, Italy.
University of Florence · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metastatic prostate cancer is a major health burden worldwide, necessitating the continuous development of effective treatment strategies. Androgen deprivation therapy remains the cornerstone of prostate cancer treatment, but novel approaches are needed for metastatic castration-resistant prostate cancer (mCRPC). Recent studies have highlighted the prevalence of mutations in DNA repair genes, including BRCA1 and BRCA2, in mCRPC patients, rendering them more susceptible to platinum-based chemotherapy and Poly (ADP-ribose) polymerase (PARP) inhibitors. Platinum-based chemotherapy, particularly in combination with taxanes, has demonstrated encouraging activity in mCRPC, as well as homologous recombination gene alterations have shown increased sensitivity to platinum compounds in these patients. The combination of platinum-based chemotherapy with PARP inhibitors represents a novel and potentially effective therapeutic strategy for this subgroup of patients. However, the optimal sequence of administering these agents and the potential for cross-resistance and cross-toxicities remain areas requiring further investigation. Prospective randomized studies are essential to elucidate the most effective treatment approach for this challenging patient population. This review aims to explore the potential of platinum-based chemotherapy in the context of prostate cancer, and more in detail in homologous recombination repair (HRR) mutated patients. We discuss the synergistic effects of combining platinum compounds with PARP inhibitors and the potential benefits of adopting specific therapeutic sequences.

Indexed as

Poly(ADP-ribose) Polymerase InhibitorsProstatic Neoplasms, Castration-ResistantAndrogen AntagonistsHumansMalePlatinumPlatinum CompoundsProspective StudiesAndrogen AntagonistsPlatinumPlatinum CompoundsPoly(ADP-ribose) Polymerase InhibitorsCombination therapyDNA damage repairMetastatic prostate cancerPARP inhibitorsPlatinum-based chemotherapy

Identifiers

PMID37934252
PMCPMC10796584
OpenAlexW4388460259

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.